Bone Therapeutics, Rigenerand partner on cell therapy process development
Bone Therapeutics and Rigenerand have formed a cell therapy process development partnership.
Tonix files patent for proprietary monoclonal antibody
Tonix Pharmaceuticals has filed a patent application for TNX-1500, a humanized monoclonal antibody (mAb) directed against the CD40-ligand, with the World Intellectual Property Organization.
Lentigen to manufacture vector for Oncternal
Oncternal Therapeutics announced an agreement with Lentigen Technology, a subsidiary of Miltenyi Biotec, to manufacture lentiviral vectors for Octernal's investigational receptor tyrosine kinase-like orphan receptor 1-targeting chimeric antigen receptor T-cell therapy program.
KSQ Therapeutics, Takeda to develop novel cancer immunotherapies
KSQ Therapeutics has entered into a broad strategic collaboration with Takeda Pharmaceutical to research, develop, and commercialize novel immune-based therapies for cancer.
Cytovia licenses CAR NK tech to NCI
Cytovia Therapeutics has signed a licensing agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to apply its gene-edited induced pluripotent stem cell-derived technology to develop glypican-3 (GPC3) chimeric antigen receptor (CAR) natural killer (NK) cell therapeutics.
LabCentral debuts platform to attract people to biotech
LabCentral has launched a platform that aims to broaden and diversify the biotech industry's base of talent.
Bayer media day focuses on cell, gene, oncology channels
Bayer highlighted its focus on cell, gene, and oncology pipelines during its virtual Pharma Media Day in Germany.
Taysha, UTSW start fund to speed up CNS gene therapies
Taysha Gene Therapies and the University of Texas Southwestern Medical Center (UTSW) have launched a fund to accelerate the development of adeno-associated virus gene therapies for monogenic diseases of the central nervous system (CNS).
Tessera closes $230M in series B round for gene writing tech
Tessera Therapeutics has raised over $230 million in series B financing to advance its gene writing technology, capable of writing therapeutic instructions into the genome to treat diseases at their source.
Pfizer invests $120M in biotech innovation
Pfizer has invested $120 million in four clinical-stage biotech companies as part of its Pfizer Breakthrough Growth Initiative.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter